Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06578871 (Surgery for the Unknown Primary in the Era of p16-positive Oropharyngeal Squamous Cell Carcinoma), which is not on this map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06578871 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation
Surgery for the Unknown Primary in the Era of p16-positive Oropharyngeal Squamous Cell Carcinoma: Reducing Ionizing Radiation (SUPERIOR): A Randomized Trial
TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2025 to 2027Enrolled90ConditionsHead and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell CarcinomaArmsIntensity Modulated Radiotherapy (IMRT) to Mucosa at Risk, Surgical Intervention, Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Paul L SwiecickiDivision of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-2286-3555
Emily BellileCancer Data Science Shared Resource, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-4350-4658
Aleksandar F DragovicDepartment of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-1502-9861
Jonathan McHughDepartment of Pathology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-6138-8833
Aaron UdagerDepartment of Pathology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-8254-5404
Michelle Lynn MierzwaDepartment of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-3923-9970
Jennifer ShahDepartment of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-3847-8865
Molly Heft-NealDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-8813-5537
Andrew RoskoDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-6432-5451
Kelly M MalloyDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-0337-9293
Keith CasperDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-2878-3863
Steven Bennett ChinnDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-4282-0640
Andrew G ShumanDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-9305-7860
Chaz StuckenDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-1448-3376
Douglas B ChepehaDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-9062-3719
Gregory T WolfDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-3219-9515
Carol Rossier BradfordOhio State University School of Medicine, Columbus, Ohio.ORCID 0000-0002-2768-4532
Avraham EisbruchDepartment of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-4102-5197
Mark E PrinceDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-1120-9008
Francis P Worden *Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-6632-4951
Matthew E Spector *Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.ORCID 0000-0001-7646-6075
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Advanced Research Training in OtolaryngologyT32DC005356 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORFAS, GABRIEL · 2002 to 2021
$3.5M
Center for Cancer Research (CCR) P3O CA046592NCI NIH HHS P30 CA046592NIDCD NIH HHS T32 DC005356
6 · The paper itself
Abstract
purposeLocoregionally advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has excellent cure rates, although current treatment regimens are accompanied by acute and long-term toxicities. We designed a phase II deescalation trial for patients with HPV+ OPSCC to evaluate the feasibility of an upfront neck dissection to individualize definitive treatment selection to improve the quality of life without compromising survival. PATIENTS AND
methodsPatients with T1-3, N0-2 HPV+ OPSCC underwent an upfront neck dissection with primary tumor biopsy. Arm A included patients with a single lymph node less than six centimeters, with no extracapsular spread (ECS) and no primary site adverse features underwent transoral surgery. Arm B included patients who had two or more positive lymph nodes with no ECS, or those with primary site adverse features were treated with radiation alone. Arm C included patients who had ECS in any lymph node and were treated with chemoradiation. The primary endpoint was quality of life at 1 year compared with a matched historical control.
resultsThirty-four patients were enrolled and underwent selective neck dissection. On the basis of pathologic characteristics, 14 patients were assigned to arm A, 10 patients to arm B, and 9 to arm C. A significant improvement was observed in Head and Neck Quality of Life (HNQOL) compared with historical controls (-2.6 vs. -11.9, P = 0.034). With a median follow-up of 37 months, the 3-year overall survival was 100% and estimated 3-year estimated progression-free survival was 96% [95% confidence interval (CI), 76%-99%].
conclusionsA neck dissection-driven treatment paradigm warrants further research as a deintensification strategy.
Indexed as
Neck DissectionOropharyngeal NeoplasmsPapillomavirus InfectionsQuality of LifeAdultAgedChemoradiotherapyFemaleHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaeSquamous Cell Carcinoma of Head and NeckTreatment Outcome
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Upfront Neck Dissection for Treatment Selection and Improvement in Quality of Life as a Novel Treatment Paradigm for Deintensification in HPV+ OPSCC. · full record | OpenQuestion